Rituximab in jab rather than infusion. Good for us?

[Tito]

It could be of interest to us.
Roche seems to be investing in a new form of Rituximab, a jab rather than an infusion. Potentially with a new patent.
http://www.dailymail.co.uk/health/a...-blood-cancer-patients.html?ito=feeds-newsxml
This could mean that they may want to expand the list of pathologies to ME and therefore fund some trials.

Tito

 

[Sherlock]

It's surprising to see that is (so far) the only article on that story on the entire internet. I know there has been some previous use in cancer of injections to specific areas in/around tumors - but not intravenous injection.

 

[rebar]

this is a very interesting development, I wonder how it will play out with this community. is this the same formula or have they tweaked it. the implications are greater than just saving time, with a new patent there would be an improved chance for trials. this is good news

 

[alex3619]

This would simplify treatment enormously. It takes a lot more hospital resources for an infusion. However I do wonder about safety. One of the reasons to infuse Rituximab slowly is that any complications can be dealt with before too much is given.

 

[Gemini]

It could be of interest to us.
Roche seems to be investing in a new form of Rituximab, a jab rather than an infusion. Potentially with a new patent.
http://www.dailymail.co.uk/health/a...-blood-cancer-patients.html?ito=feeds-newsxml
This could mean that they may want to expand the list of pathologies to ME and therefore fund some trials.
Tito

Roche Press Release posted on another site

http://www.roche.com/med-cor-2012-12-08b.htm

Statistics in this release: 300,000 users of Rituximab worldwide for diseases other than cancer.

Anyone have a list of these other diseases? Would be interesting to see what they are....

 

[Snow Leopard]

1,400 mg is a strong dose, this is actually a big step forward in terms of drug delivery, assuming the safety profile is similar.

I had heard about these clinical trials, but I was not aware of any publications.